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Abstract
Background and Objectives In a multi-center, single-arm,
prospective study, we investigated the efficacy and safety
of the fixed irbesartan/hydrochlorothiazide combination in
Chinese patients with moderate to severe hypertension.
Methods Eligible patients were aged 18–75 years, with a
blood pressure of 160–199 mmHg systolic or 100–119 mmHg
diastolic during a 1-week wash-out phase off antihypertensive
medication. The enrolled patients started antihypertensive
treatment with irbesartan/hydrochlorothiazide 150 mg/
12.5 mg once daily, with the possible addition of irbesartan
150 mg once daily and up-titration to irbesartan/hydro-
chlorothiazide 300 mg/25 mg once daily at 4 and 8 weeks of
follow-up, respectively. The primary efficacy variable was the
goal blood pressure-attaining rate at 12 weeks of follow-up
(\140/90 mmHg, or\130/80 mmHg in patients with diabetes
mellitus).
Results In the intention-to-treat analysis (n = 501) at
12 weeks of follow-up, the goal blood pressure-attaining
rate was 57.3 %, and the mean change in blood pressure
from baseline was 27.8 mmHg [95 % confidence interval
(CI) 26.4–29.1 mmHg; p \ 0.001] systolic and 13.5 mmHg
(95 % CI 12.6–14.4 mmHg; p \ 0.001) diastolic. Similar
findings were observed in the per-protocol analysis
(n = 449). The prevalence of microalbuminuria and left
ventricular hypertrophy significantly (p B 0.01) decreased
from 33.4 % (150/449) and 50.4 % (215/427) at baseline to
23.4 % (105/447) and 41.3 % (176/427) at the end of fol-
low-up, respectively. Four patients (2.0 %) reported a
serious adverse event.
Conclusion The fixed irbesartan/hydrochlorothiazide
combination may control blood pressure to the target level
in about 60 % of Chinese patients with moderate to severe
hypertension, with an acceptable safety profile.
1 Introduction
While the number of hypertensive patients is increasing in
most countries because of longevity and unhealthy life-
styles, the control rate of hypertension remains low in
many countries, such as China. According to the 2002
China National Nutrition and Health Survey, the preva-
lence of hypertension was 18.8 % among persons aged
over 18 years, whereas the control rate of hypertension was
only 6.2 % [1]. One of the major reasons for the low
control rate is that the currently recommended antihyper-
tensive drugs usually target one pathogenic pathway of
hypertension and are sufficiently efficacious only in a
fraction of hypertensive patients, even at high dosages [2,
3]. Combining two or more classes of antihypertensive
drugs with complementary mechanisms might increase the
blood pressure-lowering efficacy in specific patients and
increase the number of patients who would have a signif-
icant response to antihypertensive therapy [2, 3]. Because a
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fixed-dose combination in a single pill is probably an
efficient approach to combination therapy, several single-
pill combination drugs have been recently developed and
are increasingly used in the management of hypertension in
many countries, including China.
The combined use of an angiotensin receptor blocker
and a thiazide diuretic is considered a preferred combina-
tion by most of the current guidelines [3–5]. This class of
fixed-combination drugs has been extensively studied in
Europe [6, 7] and North America [8–11]. However, there is
still very limited clinical trial data in the Chinese popula-
tion. The fixed irbesartan/hydrochlorothiazide combination
became available in the Chinese market in 2004 [12, 13]
and is currently the most commonly prescribed agent in its
class in China. In this multi-center, single-arm, prospective
study, we investigated the efficacy and safety of the fixed
irbesartan/hydrochlorothiazide combination in Chinese
patients with moderate to severe hypertension.
2 Methods
2.1 Study Design
The present study was designed as a multi-center, open-
label, single-arm, prospective trial and was conducted from
April 2008 to February 2009 in 18 hospitals across China.
The study protocol was approved by the ethics committee
of Ruijin Hospital, Shanghai Jiaotong University School of
Medicine (Shanghai, China) and, as necessary, also by the
ethics committees of the participating hospitals. All
patients gave written informed consent.
The study consisted of a 1-week wash-out phase and a
subsequent 12-week study treatment period. The 1-week
wash-out phase included one screening visit at the begin-
ning and one visit at the end for determination of eligibility.
The 12-week study treatment period included four visits at
2, 4, 8, and 12 weeks of follow-up. At each of these clinic
visits, blood pressure—as the major determining factor for
inclusion in the study and the major efficacy variable of the
study—was measured three times consecutively after at
least 5 min of rest in the sitting position in the morning
between 08:00 and 10:00 h, using a validated automated
blood pressure monitor (HEM 7071; Omron Healthcare,
Kyoto, Japan). These three blood pressure readings 30 to
60 s apart were averaged for clinical decisions and for the
present analysis. When the arm circumference was larger
than 32 cm, a larger cuff was used.
If, at the screening visit, previously untreated patients
had a blood pressure of 160–199 mmHg systolic or
100–119 mmHg diastolic, and if patients previously treated
with antihypertensive monotherapy had a blood pressure of
140–179 mmHg systolic or 90–109 mmHg diastolic and
had discontinued their previous antihypertensive mono-
therapy, they could enter the wash-out phase for determi-
nation of eligibility. After the wash-out run-in phase,
eligible patients entered the 12-week study treatment per-
iod and started taking irbesartan/hydrochlorothiazide
150 mg/12.5 mg once daily. A tablet of irbesartan 150 mg
and an additional tablet of irbesartan/hydrochlorothiazide
150 mg/12.5 mg could be added at 4 and 8 weeks of fol-
low-up, respectively, for systolic/diastolic blood pressure
to reach the target level of \140/90 mmHg, or \130/
80 mmHg in patients with diabetes mellitus. The study
medication could also be stopped in the presence of
symptomatic hypotension or any other serious adverse
events related to the study medication. The purpose of the
clinic visit at 2 weeks of follow-up was to assure the safety
of and patient compliance with antihypertensive therapy. It
was decided that the study medication should not change at
2 weeks of follow-up, unless such a change was necessary.
Patients were instructed to take the study medication
between 08:00 and 10:00 h every morning except on the
day of the clinic visit, when the medication was adminis-
tered after blood pressure had been measured. Other anti-
hypertensive agents or drugs with a potential blood
pressure-lowering or blood pressure-increasing action were
not to be used during the 12-week study treatment period.
The study medication was supplied free of charge for the
whole study period by Sanofi China (Shanghai, China).
2.2 Study Population
Eligible patients were men and women aged 18–75 years,
with a blood pressure of 160–199 mmHg systolic or
100–119 mmHg diastolic at the clinic visit at the end of the
1-week wash-out phase. The exclusion criteria for the study
were as follows: blood pressure C200 mmHg systolic or
C120 mmHg diastolic; secondary hypertension; women
who were pregnant, lactating, or of childbearing potential
without proper contraception; cardiac diseases including
cardiomyopathy, valvular heart disease, heart failure, or
documented left ventricular ejection fraction reduction
(\45 %); severe arrhythmias such as ventricular or supra-
ventricular arrhythmia, pre-excitation syndrome, second-
degree or third-degree atrioventricular block and sick sinus
syndrome; and other significant, uncontrolled, or life-
threatening conditions or diseases. We also excluded
patients with a serum concentration of alanine or aspartate
transaminase C2 times the upper normal limits; a serum
creatinine concentration C176.8 lmol/l; creatinine clear-
ance or an estimated glomerular filtration rate\30 ml/min
per 1.73 m2; albuminuria C2? on a dipstick test; gout or
serum uric acid C406 lmol/l in men or C348 lmol/l in
women; a serum potassium concentration \3.5 mmol/l or
C5.5 mmol/l; or uncontrolled diabetes mellitus, as
110 Q.-F. Huang et al.
diagnosed by a plasma fasting glucose concentration
[11.0 mmol/l or a plasma glycosylated hemoglobin con-
centration [8.5 %; and patients who were taking antide-
pressant medication or were allergic to the study medication.
The following diseases or conditions did not lead to
exclusion: a history of stroke (excluding transient ischemic
attack) at least 6 months prior to inclusion; the presence of
coronary heart disease (a documented coronary athero-
sclerosis or stenosis); evidence of arrhythmia (on an elec-
trocardiogram); dyslipidemia (a serum total cholesterol
concentration C6.22 mmol/l, low-density lipoprotein cho-
lesterol C4.14 mmol/l, or triglycerides C2.26 mmol/l, or
use of statins); controlled diabetes mellitus (a fasting
plasma glucose concentration from 7.1 to 11.0 mmol/l or
on oral antidiabetic drugs or insulin); and chronic kidney
disease (albuminuria or a serum creatinine concentration
from 132.6 to 176.8 lmol/l in men and 123.8 to
176.8 lmol/l in women).
2.3 Efficacy and Safety Evaluations
The primary efficacy variable was the goal blood pressure-
attaining rate at the end of the 12-week study. The goal
blood pressure was defined as a systolic/diastolic blood
pressure of \140/90 or \130/80 mmHg in the absence or
presence of diabetes mellitus, respectively.
Secondary efficacy variables included changes from
baseline in systolic and diastolic blood pressure at 4, 8, and
12 weeks of follow-up, and in the echocardiographically
measured left ventricular mass and urinary albumin
excretion as measured on a first morning void urine sample
at 12 weeks of follow-up. We defined left ventricular
hypertrophy as a left ventricular mass index of at least
112 g/m2 in men and 105 g/m2 in women, and microal-
buminuria as a urinary albumin-to-creatinine ratio of at
least 2.5 mg/mmol in men and 3.5 mg/mmol in women.
All adverse events were documented for information on
symptoms, severity, relation to the study medication,
intervention, and outcome. Routine biochemical tests of
blood and urine were performed for clinical laboratory
safety evaluations. Any clinically significant changes in
physical examinations or laboratory findings were recorded
as adverse events.
2.4 Statistical Analysis
We performed intention-to-treat and per-protocol analyses
in all patients who entered the study treatment period and
in the patients who completed the 12-week study on study
drugs, respectively. The safety analysis was performed in
all patients who had ever started the study treatment.
Continuous and categorical variables were analyzed using
the Student’s t test and v2 test, respectively. Normality of
distributions was evaluated by the Shapiro–Wilk statistic.
Analysis of changes from baseline in blood pressure and
other continuous efficacy or safety variables was performed
by the paired t test if they were normally distributed and by
the Wilcoxon signed rank test if they were not normally
distributed. We performed multiple logistic regression to
study factors associated with the use of high-dose antihy-
pertensive medication. We performed subgroup analyses
according to sex (men vs. women), age (C55 years vs.
\55 years), body mass index (C25 kg/m2 vs.\25 kg/m2),
and the presence and absence of isolated systolic hyper-
tension (systolic blood pressure C160 mmHg and diastolic




Of the 632 screened patients, 501 were enrolled in the
study and started treatment with irbesartan/hydro-
chlorothiazide 150 mg/12.5 mg once daily. During the
12-week study treatment period, 52 patients (10.4 %) were
withdrawn because they withdrew their consent (n = 18,
3.6 %), did not follow the study protocol (n = 5, 1.0 %),
because of adverse events (n = 13, 2.5 %), or other rea-
sons (n = 16, 3.2 %). In total, 449 patients completed the
12-week study follow-up.
Table 1 shows the baseline characteristics of the 501
patients by sex [264 (52.7 %) were women]. Compared
with the women, the men were slightly younger
(-1.8 years; p = 0.03), had lower systolic blood pressure
(-1.9 mmHg; p = 0.05), had higher diastolic blood pres-
sure (?3.0 mmHg; p \ 0.0001) and hence narrower pulse
pressure (-4.9 mmHg; p \ 0.0001), and included more
users of antihypertensive drugs (p = 0.02) and antidiabetic
drugs (p = 0.03). However, the men and women were
similar in most baseline characteristics such as the body
mass index; pulse rate; presence of diabetes mellitus,
dyslipidemia, or chronic kidney disease; previous history
of stroke; and previous use of specific classes of antihy-
pertensive drugs (p [ 0.05).
In the intention-to-treat analysis (n = 501), during the
study treatment period, the dosage of the study medication
remained at 150 mg/12.5 mg of irbesartan/hydrochloro-
thiazide per day in 313 patients (62.5 %) and increased to
300 mg/12.5 mg and to 300 mg/25 mg of irbesartan/
hydrochlorothiazide per day in 111 patients (22.2 %) and
77 patients (15.3 %), respectively. In the per-protocol
analysis (n = 449), the corresponding numbers of patients
were 272 (60.6 %), 105 (23.4 %), and 72 (16.0 %),
respectively.
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3.2 Antihypertensive Efficacy
In the intention-to-treat analysis, the irbesartan/hydro-
chlorothiazide combination therapy reduced systolic/dia-
stolic blood pressure from 162.5/97.9 mmHg at baseline to
138.7/86.4, 135.6/84.3, 134.2/83.9, and 134.7/84.4 mmHg
at 2, 4, 8, and 12 weeks of follow-up, respectively (Fig. 1).
The mean changes from baseline in systolic/diastolic blood
pressure were -23.8/-11.6 mmHg, -26.8/-13.6 mmHg,
-28.2/-14.0 mmHg, and -27.8/-13.5 mmHg at 2, 4, 8,
and 12 weeks of follow-up, respectively (Fig. 2).
At 12 weeks of follow-up, the percentage of patients who
attained the goal systolic/diastolic blood pressure (\140/
90 mmHg, or \130/80 mmHg in patients with diabetes
mellitus) was 57.3 % (Table 2). The goal blood pressure-
attaining rates in patients treated with irbesartan/hydro-
chlorothiazide 150 mg/12.5 mg per day (n = 313), 300 mg/
12.5 mg per day (n = 111), and 300 mg/25 mg per day
(n = 77) were 68.1, 53.2, and 19.5 %, respectively. If the
goal systolic/diastolic blood pressure was defined as
140/90 mmHg in diabetic as well as nondiabetic patients,
the goal blood pressure-attaining rates were 66.1 % in all
subjects and 77.0, 62.2, and 27.3 % in patients treated with
irbesartan/hydrochlorothiazide 150 mg/12.5 mg (n = 313),
300 mg/12.5 mg per day (n = 111), and 300 mg/25 mg per
day (n = 77), respectively (Table 2; Fig. 3).
In the per-protocol analysis, similar findings were
observed with regard to blood pressure changes from
baseline and the percentages of patients who achieved the
goal blood pressure (Table 2; Fig. 3).
3.3 Determinants of Antihypertensive Efficacy
In multiple logistic regression analysis of the intention-to-
treat study sample, we identified male sex [odds ratio (OR)
1.73, 95 % confidence interval (CI) 1.16–2.56; p = 0.007]
and baseline systolic blood pressure (?10 mmHg; OR







Age (years; mean ± SD) 54.1 ± 9.8 55.9 ± 8.6 0.03
Body mass index (kg/m2;
mean ± SD)
25.8 ± 3.1 25.7 ± 3.5 0.77
Systolic blood pressure
(mmHg; mean ± SD)
161.5 ± 11.3 163.4 ± 10.0 0.05
Diastolic blood pressure
(mmHg; mean ± SD)
99.5 ± 8.6 96.5 ± 8.4 0.0001
Pulse rate (beats/min;
mean ± SD)
74.7 ± 9.7 74.1 ± 10.1 0.46
Previous or concomitant disease [n (%)]
Strokea 3 (1.2) 1 (0.4) 0.27
Coronary heart diseaseb 5 (2.1) 14 (5.3) 0.06
Arrhythmiac 12 (5.1) 9 (3.4) 0.36
Dyslipidemiad 4 (1.7) 9 (3.4) 0.23
Diabetes mellituse 35 (14.8) 50 (18.9) 0.21
Chronic kidney diseasef 77 (32.5) 98 (37.1) 0.28
Previous treatment [n (%)]g
Antihypertensive treatment 117 (49.4) 158 (59.9) 0.02
Calcium channel blockers 52 (21.9) 70 (26.5) 0.23
Angiotensin-converting
enzyme inhibitors
29 (12.2) 32 (12.1) 0.97
Angiotensin receptor blockers 27 (11.4) 25 (9.5) 0.48
b-Blockers 5 (2.1) 11 (4.2) 0.19
Diuretics 5 (3.0) 9 (3.4) 0.38
Other antihypertensive drugs 12 (5.1) 27 (10.2) 0.03
Aspirin 4 (1.7) 3 (1.1) 0.60
Statins 1 (0.4) 1 (0.4) 0.94
Antidiabetic drugs 4 (1.7) 14 (5.3) 0.03
a Excluding transient ischaemic attack
b Defined as a documented coronary atherosclerosis or stenosis
c Arrhythmia evidenced by an electrocardiogram
d Defined as a serum concentration of at least 6.22 mmol/l total choles-
terol, 4.14 mmol/l low-density lipoprotein cholesterol, or 2.26 mmol/l
triglycerides, or as the use of statins
e Defined as a fasting plasma glucose concentration from 7.1 to
11.0 mmol/l, or as the use of antidiabetic drugs or insulin
f Defined as albuminuria or a serum creatinine concentration from 132.6
to 176.8 lmol/l in men and from 123.8 to 176.8 lmol/l in women





















Fig. 1 Systolic and diastolic blood pressure at baseline and during
follow-up in the intention-to-treat analysis. The vertical lines denote
the standard deviations of the mean systolic and diastolic blood
pressure values
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1.59, 95 % CI 1.31–1.92; p \ 0.0001) and diastolic blood
pressure (?5 mmHg; OR 1.17, 95 % CI 1.04–1.32;
p = 0.007) as significant factors associated with the use of
high dosage of irbesartan/hydrochlorothiazide. In further
intention-to-treat analysis, we studied the blood pressure
changes from baseline and the percentage of patients who
achieved the goal blood pressure at the end of follow-up,
while accounting for various baseline characteristics
(Table 3). The goal blood pressure (\140/90 mmHg)-
attaining rate was significantly lower in overweight and
obese patients than in normal-weight subjects (59.6 vs.
75.1 %; p B 0.0003) and significantly lower in patients
with chronic kidney disease than in those with normal renal
function (53.1 vs. 73.0 %; p B 0.0003).
3.4 Left Ventricular Hypertrophy
and Microalbuminuria
In the per-protocol analysis, the irbesartan/hydro-
chlorothiazide combination therapy significantly reduced
the prevalence of albuminuria (n = 449) by 30 % (95 %
CI 12–46; p = 0.004) from 33.4 % at baseline to 23.4 % at
the end of follow-up, and significantly reduced the preva-
lence of left ventricular hypertrophy (n = 427) by 19 %
(95 % CI 4–32; p = 0.01) from 50.4 % to 41.3 % over the
same period.
3.5 Safety
Of the 501 patients who started treatment with the irbe-
sartan/hydrochlorothiazide combination, 163 (32.5 %)
reported at least one adverse event. Table 4 shows adverse
events with an incidence[1 % and those typically relevant
to the use of irbesartan/hydrochlorothiazide combination
therapy. Hyperuricemia was the most frequent (n = 23,
4.6 %) of the 77 adverse events (15.4 %) that were related
to the study medication. A total of 4 serious adverse events
(0.8 %) in 4 patients were reported, including 1 hemor-
rhagic stroke, 1 hypertensive emergency, 1 hypertensive
urgency, and 1 spinal disc herniation. None of these serious
adverse events led to death.
4 Discussion
Our study showed that fixed irbesartan/hydrochlorothiazide
combination therapy administered in a dosage range of
150 mg/12.5 mg to 300 mg/25 mg once daily may control
systolic/diastolic blood pressure to a level below
140/90 mmHg in approximately two thirds of Chinese
patients with moderate to severe hypertension. Increasing
the dose of irbesartan/hydrochlorothiazide in 40 % of







































Week 4 Week 8 Week 12
−23.8 
[−22.4 to −25.1] 
−28.2 
[−26.8 to −29.6] 
−27.8 
[−26.4 to −29.1] 
−26.8 
[−25.4 to −28.3] 
−11.6 
[−10.7 to −12.5] 
−13.6
[−12.7 to −14.5] −14.0[−13.1 to −15.0] 
−13.5 
[−12.6 to −14.4] 
n = 501
p < 0.0001 for all changes
Fig. 2 Mean changes from
baseline in systolic and diastolic
blood pressure in the intention-
to-treat analysis
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pressure-attaining rate from 48.1 to 66.1 % of all enrolled
patients. Even if the goal blood pressure was defined as a
systolic/diastolic pressure of \130/80 mmHg in patients
with diabetes, the rate of control of hypertension was still
nearly 60 %.
Our finding is in line with the results of the INCLUSIVE
(Irbesartan/Hydrochlorothiazide Blood Pressure Reduc-
tions in Diverse Patient Populations) trial, which was
conducted as a multi-center, prospective, open-label, sin-
gle-arm study in an American population [9]. The
INCLUSIVE trial consisted of four periods: 4–5 weeks of
placebo, 2 weeks of hydrochlorothiazide 12.5 mg/day, and
8 weeks each of irbesartan/hydrochlorothiazide 150 mg/
12.5 mg and 300 mg/25 mg per day, respectively. In the
intention-to-treat analysis, the blood pressure-lowering
efficacy was evaluated in 736 patients for the total 18-week
study treatment period from commencement of hydro-
chlorothiazide to the end of the trial. The mean changes
from baseline in systolic/diastolic blood pressure were
15.1/7.2 and 21.5/10.4 mmHg at 10 and 18 weeks of fol-
low-up, respectively. The corresponding rates of attain-
ment of goal blood pressure (\140/90, or \130/80 mmHg
in patients with diabetes) were 48 and 69 %, respectively.
The slightly higher rate of attainment of goal blood pres-
sure in the INCLUSIVE trial than in our study (69 vs.
57.3 %) may be attributable to the forced titration of
combination therapy in a large majority of the enrolled
patients and the inclusion of patients with mild hyperten-
sion in the INCLUSIVE trial [9].
Our observation in subgroup analysis is also in keeping
with the results of various subgroup analyses of the
INCLUSIVE trial [14]. In the INCLUSIVE trial, the rate of
attainment of goal blood pressure was similar across dif-
ferent ethnicities (70 % in Caucasians, 66 % in African
Americans, and 65 % in Hispanics) [15], similar in older
and younger patients (72 % in patients aged C65 years and
68 % in those aged\65 years) [16], and similar in patients
with and without isolated systolic hypertension (systolic
blood pressure control in 74 vs. 81.6 %) [17], but slightly
lower in men than in women (60 vs. 76 %) [18], slightly
lower in overweight and obese patients than in normal-
weight patients (66.7 vs. 82.5 %) [19], and (taking into
account the lower goal blood pressure thresholds in
patients with diabetes), slightly lower in diabetic patients
than in nondiabetic patients (40.1 vs. 81.7 %) [19, 20].
Our findings should also be compared with the results of a
previous Chinese study, which studied the efficacy and safety
of the fixed irbesartan/hydrochlorothiazide 150 mg/12.5 mg
combination in 926 patients with mild to moderate hyper-
tension (diastolic blood pressure 90–109 mmHg and systolic
blood pressure\180 mmHg) [13]. In the per-protocol anal-
ysis (n = 920) of that 8-week, multi-center, single-arm,
prospective study, 637 patients (69 %), 211 patients
(22.9 %), and 72 patients (7.8 %) used irbesartan/hydro-
chlorothiazide 150 mg/12.5 mg, 300 mg/12.5 mg, and
300 mg/25 mg per day, respectively. The irbesartan/hydro-
chlorothiazide combination therapy reduced systolic/dia-
stolic blood pressure by 22/16 mmHg from 149/95 mmHg at
Table 2 Percentages of patients who attained the goal blood pressure
Rate of attainment of goal blood pressure Follow-up time (weeks)
2 4 8 12
Intention-to-treat analysis (n = 501)
Goal blood pressure \140/90 mmHg, or
\130/80 mmHg in diabetic patients (%)
39.7 55.7 59.7 57.3
Goal blood pressure \140/90 mmHg (%) 45.7 62.5 66.3 66.1
Per-protocol analysis (n = 449)
Goal blood pressure \140/90 mmHg, or
\130/80 mmHg in diabetic patients (%)
42.8 60.5 65.3 62.6

























































Fig. 3 Percentage of patients who achieved the goal blood pressure
(\140/90 mmHg) at various dosages: a intention-to-treat analysis;
b per-protocol analysis
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baseline to 127/79 mmHg at 8 weeks of follow-up. In that
previous study, which included patients with mild hyper-
tension, 6.7 % of patients reported adverse events [13].
Our study should be interpreted within the context of its
limitations. The evaluation of blood pressure-lowering
efficacy relied mainly on blood pressure measurement in
the clinic. We did not perform ambulatory blood pressure
monitoring nor other hemodynamic investigations. Another
major limitation of our study was its noncomparative
design. Without a proper control group, placebo effects,
observer bias, and regression to the mean may influence the
evaluation of blood pressure-lowering efficacy. However,
observations in noncomparative studies, such as the
amplitude of changes in blood pressure from baseline and
the rate of attainment of goal blood pressure, are similar to
those in routine clinical practice. Despite the noncompar-
ative design of our study, our findings are also in keeping
with observations in the irbesartan/hydrochlorothiazide
combination arms of controlled studies [21–26]. In those
studies, the fixed irbesartan/hydrochlorothiazide combina-
tion alone normalized blood pressure in 51.4 and 50.2 % of
patients with hypertension previously uncontrolled by
monotherapy who were receiving clinic blood pressure
monitoring (\140/90 mmHg) or home blood pressure
monitoring (\135/85 mmHg), respectively [7, 21], and
also in 53.4 % of patients with moderate hypertension [10]
and in 34.6 % of patients with severe hypertension [11,
22]. In addition, those studies also confirmed that the blood
pressure-lowering efficacy of the fixed irbesartan/hydro-
chlorothiazide combination was largely independent of sex
[21], age [21, 23, 24], and methods of blood pressure
measurement [6–8]; slightly less prominent in obese or
diabetic patients [23–25]; and more prominent in patients
with a higher initial blood pressure [23, 26].
In line with the results of previous studies [27, 28], the
safety data from our study demonstrated that the irbesartan/
hydrochlorothiazide combination was well tolerated even
at the high dose, and was associated with few and mild
Table 3 Subgroup analysis on the blood pressure-lowering efficacy in the intention-to-treat analysis
Parameter n Change in blood pressure Rate of attainment of goal blood pressure
Systolic Diastolic \140/90 mmHg \130/80 mmHg (in diabetic
patients)
mmHg; mean ± SD p value mmHg; mean ± SD p value Patients (%) p value Patients (%) p value
Sex
Male 237 -26.6 ± 15.1 0.07 -13.7 ± 10.9 0.59 63.7 0.29 54.0 0.16
Female 264 -28.8 ± 15.8 -13.3 ± 10.1 68.2 60.2
Age
\55 years 246 -28.3 ± 15.4 0.75 -15.9 ± 9.6 \0.0001 68.3 0.30 59.8 0.27
C55 years 255 -27.3 ± 15.6 -11.2 ± 10.8 63.9 54.9
Body mass index
\25 kg/m2 209 -29.4 ± 15.0 0.10 -14.1 ± 10.5 0.30 75.1 0.0003 64.1 0.009
C25 kg/m2 292 -26.6 ± 15.7 -13.0 ± 10.5 59.6 52.4
Isolated systolic hypertensiona
No 414 -28.0 ± 15.7 0.97 -15.8 ± 9.5 \0.0001 66.4 0.71 58.0 0.5
Yes 87 -26.9 ± 14.7 -2.65 ± 8.0 64.4 54.0
Diabetes mellitusb
No 416 -27.0 ± 15.3 0.007 -13.7 ± 10.5 0.30 65.1 0.33 65.1 \0.0001
Yes 85 -31.3 ± 15.8 -12.4 ± 10.2 70.6 18.8
Left ventricular hypertrophyc
No 233 -27.2 ± 14.6 0.34 -13.4 ± 10.3 0.87 66.5 0.71 57.9 0.72
Yes 245 -28.4 ± 16.4 -13.6 ± 11.0 64.9 56.3
Chronic kidney diseased
No 326 -28.7 ± 14.1 0.07 -13.6 ± 10.3 0.77 73.0 \0.0001 62.6 0.001
Yes 175 -26.0 ± 17.7 -13.3 ± 10.9 53.1 47.4
a Defined as a systolic blood pressure of at least 160 mmHg and a diastolic blood pressure less than 90 mmHg
b Defined as a fasting plasma glucose concentration from 7.1 to 11.0 mmol/l, or as the use of antidiabetic drugs or insulin
c Defined as a left ventricular mass index of at least 112 g/m2 in men and 105 g/m2 in women
d Defined as albuminuria or a serum creatinine concentration from 132.6 to 176.8 lmol/l in men and from 123.8 to 176.8 lmol/l in women
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adverse events. Hyperuricemia was the most frequently
recorded adverse event. Nonetheless, gout was reported in
only one patient.
5 Conclusion
The fixed irbesartan/hydrochlorothiazide combination may
control blood pressure to the target level in about 60 % of
Chinese patients with moderate or severe hypertension,
with an acceptable safety profile. These blood pressure
changes are clinically important in the protection of target
organs and in the prevention of cardiovascular events, as
evidenced by the significant changes in the prevalence of
left ventricular hypertrophy and albuminuria observed in
our short-term follow-up study.
Acknowledgments The authors gratefully acknowledge the partic-
ipation of the patients and the contribution of the investigators from
18 hospitals. The principal investigators (listed in the order of the
number of enrolled patients) were Shou-Chun Xu from Beijing
Aerospace 731 Hospital (50 patients); Gen-Shan Ma from Nanjing
Zhongda Hospital of Southeast University (40 patients); Qiu-Yan Dai
from Shanghai First People’s Hospital (35 patients); Meng Wei from
Shanghai Sixth People’s Hospital (35 patients); Biao Xu from Nan-
jing Gulou Hospital (31 patients); Yu-Gang Dong from The First
Affiliated Hospital of Sun Yat-Sen University, Guangzhou (28
patients); Jian Hu from The First Hospital of China Medical Uni-
versity, Shenyang (27 patients); Yong Huo from Beijing University
First Hospital (27 patients); Guo-Sheng Fu from Hangzhou Shao
Yi-Fu Hospital (27 patients); Yi Luo from Guangzhou First People’s
Hospital (26 patients); Wen-Ling Zhu from Beijing Union Medical
College Hospital (26 patients); Shang-Lang Cai from The Affiliated
Hospital of Qingdao University School of Medicine (25 patients); Li-
Sheng Liu from Beijing Hypertension League Institute (25 patients);
Xin-Chun Yang from Beijing Chao-Yang Hospital (25 patients); Tao
Guo from The First Affiliated Hospital of Kunming Medical College
(17 patients); Ying-Ling Zhou from Guangdong Province General
Hospital, Guangzhou (17 patients); and Yu-Hua Liao from Wuhan
Union Hospital (14 patients). The study was funded and sponsored by
Sanofi China (Shanghai). Dr. Wang reports receiving consulting and
lecture fees from Sanofi China (Shanghai). The other authors declare
no conflicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
The exclusive right to any commercial use of the article is with
Springer.
References
1. Wu Y, Huxley R, Li L, Anna V, Xie G, Yao C, Woodward M, Li
X, Chalmers J, Gao R, Kong L, Yang X, China NNHS Steering
Committee, China NNHS Working Group. Prevalence, aware-
ness, treatment, and control of hypertension in China: data from
the China National Nutrition and Health Survey 2002. Circula-
tion. 2008;118:2679–86.
2. Palatini P. Combination therapy in the management of hyper-
tension: focus on angiotensin receptor blockers combined with
diuretics. J Clin Hypertens (Greenwich). 2005;7:96–101.
3. Gradman AH, Basile JN, Carter BL, Bakris GL, American
Society of Hypertension Writing Group. Combination therapy in
hypertension. J Clin Hypertens (Greenwich). 2011;13:146–54.
4. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M,
Caulfield MJ, Cifkova R, Cle´ment D, Coca A, Dominiczak A,
Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A,
Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K,
Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L,
Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa
M, Zanchetti A, European Society of Hypertension. Reappraisal
of European guidelines on hypertension management: a European
Society of Hypertension Task Force document. J Hypertens.
2009;27:2121–58.
5. Writing Group of the 2010 Chinese Guidelines for the Manage-
ment of Hypertension. Chinese guidelines for the management of
hypertension (in Chinese). Chin J Cardiol. 2010;2011(39):
579–616.
6. Coca A, Calvo C, Sobrino J, Go´mez E, Lo´pez-Paz JE, Sierra C,
Bragulat E, de la Sierra A. Once-daily fixed-combination irbe-
sartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood
pressure profile in patients with essential hypertension. Clin Ther.
2003;25:2849–64.
7. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N,
Asmar R, COmparative Study of Efficacy of Irbesartan/HCTZ
with Valsartan/HCTZ Using Home Blood Pressure Monitoring in
the TreAtment of Mild-to-Moderate Hypertension (COSIMA)
Investigators. A home blood pressure monitoring study compar-
ing the antihypertensive efficacy of two angiotensin II receptor
antagonist fixed combinations. Am J Hypertens. 2005;18:1482–8.
8. Neutel JM, Smith D. Ambulatory blood pressure comparison of
the anti-hypertensive efficacy of fixed combinations of irbesartan/
hydrochlorothiazide and losartan/hydrochlorothiazide in patients
with mild-to-moderate hypertension. J Int Med Res. 2005;33:
620–31.
Table 4 Adverse events in the safety dataset (n = 501)
Adverse eventa Patients
[n (%)]
Events possibly related to the
study medication [n (%)]
Dizziness 41 (8.2) 11 (2.2)
Hyperuricemia 25 (5.0) 23 (4.6)




Severe hypertension 5 (1.0) 4 (0.8)
Palpitation 5 (1.0) 3 (0.6)
Fatigue 5 (1.0) 2 (0.4)
Elevation of alanine or
aspartate transaminase
4 (0.8) 3 (0.6)
Hypokalemia 3 (0.6) 2 (0.4)
Hyperkalemia 1 (0.2) 1 (0.2)
Gout 1 (0.2) 1 (0.2)
Total 163 (32.5) 77 (15.4)
a The adverse events reported in this table are those with an incidence
[1 % and those relevant to the use of irbesartan/hydrochlorothiazide
combination therapy
116 Q.-F. Huang et al.
9. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC,
Ofili EO, Sowers JR, Weber MA, INCLUSIVE Investigators. The
efficacy and safety of low- and high-dose fixed combinations of
irbesartan/hydrochlorothiazide in patients with uncontrolled sys-
tolic blood pressure on monotherapy: the INCLUSIVE trial.
J Clin Hypertens (Greenwich). 2005;7:578–86.
10. Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A.
A comparison of the efficacy and safety of irbesartan/HCTZ
combination therapy with irbesartan and HCTZ monotherapy in
the treatment of moderate hypertension. J Hum Hypertens.
2008;22:266–74.
11. Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A,
Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination
therapy as initial treatment for rapid control of severe hyperten-
sion. J Clin Hypertens (Greenwich). 2006;8:850–7; quiz 858–9.
12. Tang B, Zhu J, Cai N, Fan W, Sun N, Liu G, Ma H. Effect and
safety of irbesartan/hydrochlorothiazide combination therapy on
mild to moderate essential hypertension (in Chinese). Chin Circ J.
2004;19:430–2.
13. Sun NL, Jing S, Chen J. The control rate of irbesartan/hydro-
chlorothiazide combination regimen in the treatment of Chinese
patients with mild to moderate hypertension (in Chinese). Chin J
Cardiol. 2005;33:618–21.
14. Saunders E, Cable G, Neutel J. Predictors of blood pressure
response to angiotensin receptor blocker/diuretic combination
therapy: a secondary analysis of the Irbesartan/Hydro-
chlorothiazide Blood Pressure Reductions in Diverse Patient
Populations (INCLUSIVE) study. J Clin Hypertens (Greenwich).
2008;10:27–33.
15. Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris GL,
Cushman WC, Sowers JR, Weber MA. Irbesartan/HCTZ fixed
combinations in patients of different racial/ethnic groups with
uncontrolled systolic blood pressure on monotherapy. J Natl Med
Assoc. 2006;98:618–26.
16. Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC,
Ofili EO, Sowers JR, Madder R, Weber MA. Efficacy and safety
of fixed combinations of irbesartan/hydrochlorothiazide in older
vs younger patients with hypertension uncontrolled with mono-
therapy. Am J Geriatr Cardiol. 2008;17:27–36.
17. Chrysant SG, Neutel JM, Ferdinand KC. INCLUSIVE investi-
gators. Irbesartan/hydrochlorothiazide for the treatment of iso-
lated systolic hypertension: a subgroup analysis of the
INCLUSIVE trial. J Natl Med Assoc. 2009;101:300–7.
18. Ofili EO, Cable G, Neutel JM, Saunders E. Efficacy and safety of
fixed combinations of irbesartan/hydrochlorothiazide in
hypertensive women: the INCLUSIVE trial. J Womens Health
(Larchmt). 2008;17:931–8.
19. Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of
irbesartan/hydrochlorothiazide in hypertensive patients stratified
by body mass index and type 2 diabetes mellitus status: a post hoc
subgroup analysis of the Irbesartan/HCTZ Blood Pressure
Reductions in Diverse Patient Populations trial. Clin Ther. 2008;
30:2354–65.
20. Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC,
Ferdinand KC, Ofili EO, Weber MA, INCLUSIVE Investigators.
Antihypertensive efficacy of Irbesartan/HCTZ in men and women
with the metabolic syndrome and type 2 diabetes. J Clin Hy-
pertens (Greenwich). 2006;8:470–80.
21. Asmar R, Oparil S. Comparison of the antihypertensive efficacy
of irbesartan/HCTZ and valsartan/HCTZ combination therapy:
impact of age and gender. Clin Exp Hypertens. 2010;32:499–503.
22. Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S. Safety
and tolerability of fixed-dose irbesartan/hydrochlorothiazide for
rapid control of severe hypertension. Clin Exp Hypertens.
2009;31:572–84.
23. Franklin SS, Neutel JM. Efficacy and safety of irbesartan/HCTZ
in severe hypertension according to cardiometabolic factors.
J Clin Hypertens (Greenwich). 2010;12:487–94.
24. Weir MR, Neutel JM, Bhaumik A, De Obaldia ME, Lapuerta P.
The efficacy and safety of initial use of irbesartan/hydro-
chlorothiazide fixed-dose combination in hypertensive patients
with and without high cardiovascular risk. J Clin Hypertens
(Greenwich). 2007;9(Suppl 5):23–30.
25. Neutel JM. A comparison of the efficacy and safety of irbesartan/
hydrochlorothiazide combination therapy with irbesartan mono-
therapy in the treatment of moderate or severe hypertension in
diabetic and obese hypertensive patients: a post-hoc analysis
review. Postgrad Med. 2011;123:126–34.
26. Franklin S, Lapuerta P, Cox D, Donovan M. Initial combination
therapy with irbesartan/hydrochlorothiazide for hypertension: an
analysis of the relationship between baseline blood pressure and
the need for combination therapy. J Clin Hypertens (Greenwich).
2007;9(Suppl 5):15–22.
27. Bramlage P. Fixed combination of irbesartan and hydrochloro-
thiazide in the management of hypertension. Vasc Health Risk
Manag. 2009;5:213–24.
28. Croxtall JD, Keating GM. Irbesartan/Hydrochlorothiazide: in
moderate to severe hypertension. Drugs. 2008;68:1465–72.
Irbesartan/Hydrochlorothiazide in Chinese Patients 117
